While some data suggest that overall drug price increases may have moderated recently, prices for specific drugs continue to rise at rates above inflation.
List price increases for many Medicare Part D drugs—both brands and generics—exceeded inflation in 2016 and 2017, in some cases by a substantial margin, according to a recent analysis from the Kaiser Family Foundation.
The inflation rate between July 2016 and July 2017 was 1.7%, and of the 2879 drugs reported in 2017’s Medicare Part D drug spending dashboard, 60% (1733 drugs) had list price increases that exceeded inflation.
One-fourth had price increases of at least 10% between 2016 and 2017; more than one-third (35%) had price increases above the rate of inflation but below 10%.
Another 284 drugs (10%) had price increases below inflation. For the remainder (859 drugs, or 30%), list prices decreased between 2016 and 2017.
The top 25 drugs by total Medicare Part D in 2017 were brand-name drugs; the majority of those (20) had list price increases between 2016 and 2017 that exceeded the inflation rate, in some cases by double digits. For 20 of the 25 drugs, price increases ranged from 3 times to more than 9 times the rate of inflation.
Pregabalin (Lyrica) rose 15.7%, lenalidomide (Revlimid) rose 15.3%, adalimumab (Humira Pen) rose 13.2%, and insulin aspart (Novolog Flexpen) rose by 11.0%. Looking at 2014 to 2017, those same 4 brands had list price increases in the double digits: Humira Pen (18.8%), Lyrica (15.9%), Novolog Flexpen (14.8%), Revlimid (11.6%).
Among the 96 drugs used by more than 1 million Part D enrollees in 2017, 22 had list price increases between 2016 and 2017 above the rate of inflation. Of those, 17 were generics (77%); half of the products (11) had list price increases below 5%, while price increases for the remaining ranged from 6% to 32%—or 3 to 18 times the rate of inflation.
The report said that while some data suggest that overall drug price increases may have moderated recently, prices for specific drugs continue to rise at rates above inflation.
As has been proposed in various pieces of recent legislation and proposals (including H.R. 3, the Lower Drug Costs Now Act of 2019, S. 2542, the Prescription Drug Pricing Reduction Act of 2019, and well as proposals from the Trump administration), Medicare could save money if drug manufactures limited price increases to the rate of inflation or paid a rebate to the federal government.
It isn’t known how drug companies will respond to such proposals, however, such as by increasing launch prices for new drugs or reducing existing rebates.
Any effect on price would depend on which drugs are included in any policies, as well as the price measure used to compare against inflation, and the base year used for calculating rebates.
In a preliminary estimate of the Senate Finance Committee legislation, the Congressional Budget Office (CBO) estimated a $57.5 billion reduction in Medicare spending between 2020-2029 due to the Part D inflation rebate proposal, and a $10.7 billion reduction due to the Part B inflation rebate proposal.
CBO has not yet estimated the effects of the inflation rebate proposals in H.R. 3.
Medicare beneficiaries could also benefit from policies that limit the growth in list prices, because cost sharing under Part D often comes in the form of coinsurance, which is calculated as a percentage of the list price. Thus, if there is slower growth in overall Part D program costs, beneficiaries could also see lower Part D plan premiums.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.